32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Innovations associated with the bayesian approach can improve the efficiency of drug development and the accuracy of clinical trials, even in the context of substantial data missingness. 3 key findings →
Design: clinical trial Participants: 854 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Physical exercise and cognitive and social enrichment activities can enhance cognitive function in patients with chronic stroke, but their cost-effectiveness compared with a balance and tone program is uncertain. 5 key findings →
Participants: 120 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, patients with Alzheimer dementia who took brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo in agitation over 12 weeks. 3 key findings →
Participants: 228 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After 3 months, IG improved gait speed (p = 0.016), implying a statistically significant difference between groups in favour of IG (p = 0.003). 3 key findings →
Design: randomized controlled trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 137 randomized participants, 2 were excluded for not meeting eligibility criteria, leaving 135 (mean [SD] age, 69.3 [3.8] years; 83 female [61%]) eligible for analysis. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donanemab treatment significantly slowed clinical progression at 76w and had a safety profile consistent with earlier studies. 5 key findings →
Participants: 1,182 Evidence: high
Full summary, score breakdown and related studies → Original source
Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. 2 key findings →
Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The present findings provide evidence of the benefits of NIBS, especially tDCS, for beneficial effect on cognition in patients with AD. 3 key findings →
Design: meta-analysis Participants: 12 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study provides the first active comparator data on amyloid plaque clearance in patients with early symptomatic AD. 2 key findings →
Design: clinical trial Participants: 148 Evidence: high
Full summary, score breakdown and related studies → Original source
The results of the included studies were summarized using a narrative synthesis or meta-analysis, as appropriate. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Caregiver stress is associated with negative outcomes for both caregivers and care recipients. 5 key findings →
Design: randomized controlled trial Participants: 14 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease (AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of symptoms by decades. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This randomized controlled trial aims to investigate the effect of 12 weeks of therapeutic exercise on cognitive function and daily activities in patients with mild Alzheimer's disease (AD). 4 key findings →
Design: randomized controlled trial Participants: 57 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Fourteen- and 16-second cut points for the CST are suitable to identify people at higher risk of functional decline among older adults in Mexico and Toledo, Spain. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The S@H study is the first randomized trial of a firearm safety decision aid for ADRD caregivers. 3 key findings →
Design: randomized controlled trial Participants: 117 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Once-weekly 5-mg/d donepezil TDS demonstrated minimal skin irritation under conditions of use of 3 consecutive weekly patch applications to the same skin site and minimal sensitization potential. 2 key findings →
Design: clinical trial Participants: 198 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study revealed that 18 weeks of gum chewing with Olibanum did not change the neuropsychological status. 5 key findings →
Participants: 36 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The dominant risk factors for late-onset Alzheimer's disease (AD) are advanced age and the APOE4 genetic variant. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This review provides a comprehensive state-of-the-art conceptual review of radiological features, clinical detection and classification challenges, pathophysiology, underlying biological mechanism(s) and risk factors/predictors associated with ARIA. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Our study suggests that SSAE-3 and SSAE-5 are valid ARIA-E rating scales for use in routine clinical practice by experienced radiologists in specialized settings. 4 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Caregivers and neurologists considered incremental clinical benefit over SOC and safety to be highly desirable qualities for a new drug that could clear amyloid plaques and delay clinical progression and indicated a willingness to accept incremental ARIA-E to achieve additional clinical benefits. 2 key findings →
Participants: 137 Evidence: low
Full summary, score breakdown and related studies → Original source
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology.
Full summary, score breakdown and related studies → Original source Free full text
One of the five patients with AD treated with LDRT experienced a temporary improvement in SNSB-II. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Studies suggest that reminiscence strategies combined with an intergenerational approach may yield significant social and mental health benefits for participants. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated